Clinical pathway for enhanced recovery after surgery for gastric cancer: A prospective single‐center phase II clinical trial for safety and efficacy. Issue 4 (12th January 2020)

• Record Type: Journal Article
• Authors: Roh, Chul Kyu; Son, Sang‐Yong; Lee, Sook Young; Hur, Hoon; Han, Sang‐Uk
• Is Part Of: Journal of surgical oncology. Volume 121:Issue 4(2020)
• Page Start: 662
• Page End: 669
• Publication Date: 2020-01-12
• Subjects: clinical pathway -- clinical trial -- enhanced recovery after surgery -- gastrectomy -- gastric cancer; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.25837
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background: We aimed to evaluate the safety and efficacy of a clinical pathway (CP) for enhanced recovery after surgery (ERAS) in gastric cancer patients, including early oral feeding and discharge on postoperative day 4. Methods: We performed a prospective, single‐center, phase II clinical trial. Based on proposed indications for an ERAS CP in our retrospective study, we enrolled 133 patients younger than 65 years who were undergoing minimally invasive subtotal gastrectomy. The primary endpoint was the ERAS CP completion rate. Secondary endpoints included complication, mortality, hospital stay, and readmission. Results: Among 133 patients, six patients were dropped out from this study. The ERAS CP completion rate (77.2%, 98 of 127) was comparable to the historical control group that completed a conventional CP (85.4%, P = .085). The postoperative complication incidence (13.4%, 15 of 127) was also similar to that of the conventional CP group (9.5%, P = .174). We identified reduced hospital stays (4.7 ± 1.3 vs 7.2±2.3 days; P < .001) and lower hospital costs ($7771 vs 8539; P < .001) in the ERAS CP group compared with the conventional CP group. Conclusions: An ERAS CP can be safely and effectively adopted for patients with gastric cancer without increasing the complication rate and could shorten hospital stays. Trial Registration: ClinicalTrials.gov (NCT01642953).